Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

20 Jul 2016

Abstract excerpt

// Florian Engert 1, 2, 3 , Michal Kovac 4 , Daniel Baumhoer 4 , Michaela Nathrath 5, 6, 7 , Simone Fulda 1, 2, 3 1 Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany 2 German Cancer Consortium (DKTK), Heidelberg, Germany 3 German Cancer Research Center (DKFZ), Heidelberg, Germany 4 Bone Tumour Reference Centre at the Institute of Pathology, University Hospital Basel,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27447864
DOI: 10.18632/oncotarget.10720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeuticsPMID 27447864Read ↗

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read ↗

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case ReportSemantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read ↗

Evidence to date: talazoparib in the treatment of breast cancerSemantic proximity Read ↗

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.Semantic proximity Read ↗

Therapeutic vulnerability to PARP1/2 inhibition in <i>RB1</i> -mutant osteosarcomaSemantic proximity Read ↗

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.Semantic proximity Read ↗

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s SarcomaSemantic proximity Read ↗

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerSemantic proximity Read ↗

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.